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Abstract 37 
Although experimental data regarding cross-protection of horse WNV vaccines against 38 
lineage 2 infections exist, their cross-protective efficacy under field conditions has not 39 
been demonstrated. This study was conducted to evaluate the capability of an inactivated 40 
lineage 1 vaccine (Equip® WNV) to protect against natural infections from the Nea 41 
Santa-Greece-2010 lineage 2 strain. In total 185 WNV-seronegative horses in 42 
Thessaloniki-Greece, were selected during two consecutive years (2011-2012). One 43 
hundred and forty were immunized and 45 were used as controls. Horses were examined 44 
for signs compatible with WNV-infection. Neutralizing antibody titers against the Greek 45 
strain and the PaAn001/France lineage 1 strain were determined in immunized horses. 46 
WNV circulation was detected during both years in the study area. It was estimated that 47 
37% and 27% of the horses were infected during 2011 and 2012, respectively. Three 48 
control animals developed clinical signs and WNV-diagnosis was confirmed. Signs 49 
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related to WNV infection were not observed in vaccinated animals. Non-vaccinated 50 
animals were associated with a 7.58±1.82% higher chance of exhibiting signs compared 51 
to immunized (P<0.05). Neutralizing antibodies raised against both strains in all 52 
immunized horses were detectable one month after the initial vaccination course. The 53 
cross-protective capacity of the lowest titer (1:40) was evident in 19 animals which were 54 
subsequently infected, and did not exhibit signs. Neutralizing antibodies were detectable 55 
until the annual booster, where strong anamnestic responses were observed 56 
(GMTRlin.1=30.2, GMTRlin.2=27.5). Results indicate that Equip® WNV is capable of 57 
inducing cross-protection in horses, against natural infections from a virulent lineage 2 58 
WNV strain. 59 
 60 
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 65 
Introduction 66 
West Nile virus (WNV) is a single-stranded RNA virus within the Japanese 67 
encephalitis virus serocomplex, which belongs to the genus Flavivirus (family 68 
Flaviviridae) (1). WNV is maintained in nature by enzootic transmission cycles between 69 
certain bird species and ornithophilic mosquitoes (2). Mosquitoes mainly belonging to the 70 
genus Culex can also act as bridge vectors, transmitting the virus to other animal species, 71 
including incidental hosts (3-6). Humans and horses are regarded as incidental (dead-end) 72 
hosts, as the virus titer developed in their blood is generally too low to infect mosquitoes 73 
(7). Nevertheless, WNV infection in susceptible hosts may eventually cause neurological 74 
disease (8). Regarding horses, the reported clinical signs may vary and these include 75 
fever, paraparesis or tetraparesis and ataxia, recumbency and behavioral changes, while 76 
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in many clinically affected horses muscle fasciculation and tremors are also present. It is 77 
expected that deaths will occur in a small percent of the affected animals (9-13). 78 
Phylogenetic analyses of WNV strains isolated worldwide have resulted in the 79 
identification of 8 genetic lineages of the virus so far (14). Until 2004, only viral strains 80 
belonging to lineages 1 and 3 had been found in Europe. The majority of the strains 81 
isolated from European outbreaks belong to lineage 1 (15, 16). Lineage 2 includes strains 82 
from sub-Saharan Africa and Madagascar, and these had been so far considered of low-83 
virulence (17). Such strains belonging to lineage 2 were isolated in Hungary (2004), in 84 
Austria (2008), as well as in Italy (2008) (16, 18). However, a virulent lineage 2 strain 85 
(Nea Santa-Greece-2010) was found to be responsible for the occurrence of 4 consecutive 86 
epidemic periods (2010-2013) in Greece, with neuroinvasive disease (WNND) cases in 87 
humans and horses during all these years (19-20). An amino acid substitution (H249P) in 88 
the NS3 protein, absent from other closely related European strains, is suspected to be 89 
associated with the high virulence and neuroinvasiveness of the Greek strain (19). 90 
Enzootic transmission of the virus was detected once again in Central Macedonia, the 91 
epicenter of 2010 epidemic, during June 2014, using backyard chickens (21). 92 
Experimental vaccinations in birds have been applied outside Europe (although 93 
bird vaccines against WNV are not commercially available) to a limited extent, especially 94 
in endangered bird species (e.g. in California condors) to protect them from fatal WNV 95 
infection, or in bird reservoir hosts (e.g. American crows and robins), aiming to reduce 96 
WNV viremia in them and prevent subsequent transmission of the virus to competent 97 
vectors (22-26). Regarding dead-end hosts, for humans only passive immunization 98 
(intravenous immunoglobulin or hyperimmune gammaglobulin administration) has been 99 
used to a limited extent for treatment of patients with WNND (27). No human vaccines 100 
against WNV are commercially available at this time, and as a result, active 101 
immunization of humans is not possible (28). In contrast, several inactivated and 102 
recombinant WNV vaccines for horses have been produced, evaluated and licensed in the 103 
USA. Specifically, two inactivated vaccines have been licensed and are being used at this 104 
time point in the USA; West Nile-Innovator® (Fort Dodge, IA, USA), and Vetera® WNV 105 
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(Boehringer Ingelheim Vetmedica, MO, USA). A recombinant vaccine with a Canarypox 106 
virus vector (Recombitek® Equine West Nile virus, Merial, GA, USA) is also marketed 107 
(19, 26, 29). It has been shown that all these immunologicals induce the production of 108 
WNV-specific neutralizing antibodies (NAbs) (30) and have proven to be very effective 109 
in protecting horses from meningoencephalitis in North America (31). Additionally, a 110 
DNA vaccine (West Nile-Innovator DNA®, Fort Dodge, IA, USA) was approved by the 111 
USDA in 2005. Finally, a chimeric vaccine (PreveNile™, Intervet, KS, USA) containing a 112 
strain of Yellow Fever virus (YFV-17D) was approved for marketing in 2006 by USDA, 113 
and was later remarketed as killed vaccine, under the name “EquiNile™” (19, 26, 32). All 114 
these immunologicals have been developed using lineage 1 WNV strains. 115 
Along with the emergence of virulent lineage 2 WNV strains in Europe, two of 116 
the aforementioned vaccines, West Nile-Innovator [under the name Equip® WNV 117 
(Zoetis)] as well as Recombitek Equine West Nile virus [under the name Proteq West 118 
Nile™, (Merial)] were authorized in 2011 and are being commercialized in European 119 
countries (33, 34). Concomitantly, questions arose whether these commercially available 120 
WNV vaccines for horses are effective in protecting them against virulent strains 121 
belonging to lineage 2, since both of them contain lineage 1 antigens, and their protection 122 
had not been extensively evaluated for other lineages. Previous experimental studies 123 
indicated that both of these vaccines can lead to the development of cross-protective 124 
immunity. Specifically, the recombinant vaccine “ALVAC®-WNV” (Merial) is capable 125 
of immunity induction in horses challenged with the goshawk-Hungary/04 lineage 2 126 
strain (35). Another study which was conducted in mice immunized with the inactivated 127 
vaccine “Duvaxyn/Equip® WNV” has shown that it provided complete protection against 128 
challenge with the SPU93/01 lineage 2 strain (36). A more recent study was conducted in 129 
horses, showing that immunization with the Equip® WNV vaccine resulted in reduction 130 
of the number of viremic animals, the duration and severity of clinical signs of disease 131 
and mortality, following experimental infection with the virulent Nea Santa-Greece-2010 132 
lineage 2 WNV strain (37). As a result, Equip® WNV was recently authorized also for 133 
lineage 2, although the duration of immunity has not been established for these strains 134 
5 
 
6 
 
(33). Nevertheless, results regarding the evaluation of the cross-protection of these 135 
vaccines in field conditions are lacking.  136 
It has been evidenced that, under experimental conditions, the effects of needle 137 
WNV inoculation in chickens might differ significantly from those of mosquito-borne 138 
natural infections (38). It has also been demonstrated that experimental WNV challenge 139 
in horses via needle inoculation, or mosquito feeding were not able to induce significant 140 
clinical signs (30). In addition, under experimental conditions, cell culture-adapted and 141 
passaged viruses are used as challenge strains. All these cultivation procedures might 142 
have consequent effects on the virulence of the viral strains. Consequently, field 143 
evaluation of viral vaccines is of utmost importance, in order to truly estimate the degree 144 
of cross-protection among different strains. In the present study we evaluated the capacity 145 
of the inactivated Equip® WNV vaccine to offer cross-protective immunity in horses 146 
against natural infections from the highly virulent Nea Santa-Greece-2010 lineage 2 147 
WNV strain in field conditions. 148 
 149 
Materials and methods 150 
Animals 151 
In total 185 mix-bred horses aged 5-18 years old were included in this 2-year 152 
study, which took place during the 2011 and 2012 epidemic periods in Greece. The 153 
horses belonged in 6 horse riding clubs in Central Macedonia the epicenter of the 2010 154 
Greek epidemic. None of the horses had been previously exposed to WNV, as indicated 155 
by serological testing with competitive enzyme-linked immunosorbent assay (cELISA) 156 
and serum neutralization test (SNT) as described below. Specifically, serological testing 157 
was conducted twice; i) one week prior to the initiation of the immunizations in both 158 
years, and ii) at the time the first dose of the primary vaccination was conducted, for both 159 
years. The health status of each horse was determined prior to its incorporation in the 160 
study. Immunizations, blood samplings and clinical examinations of the animals were 161 
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performed by experienced veterinarians. A mixture comprised of oats, muesli and 162 
hay/alfalfa hay, was being administrated to the horses, and water was available ad 163 
libitum. Trained technicians were responsible for animal husbandry procedures. 164 
 165 
Vaccine and immunization plan 166 
The commercially available ready-to-use vaccine Equip® WNV (Zoetis, Louvain-167 
la-Neuve, Belgium) was used in this 2-year study. This vaccine contains the inactivated 168 
lineage 1 WNV strain New York 1999/VM-2 (isolated from the brain of an infected horse 169 
during the 1999 epidemic period in New York, USA) formulated in MetaStim™ oil 170 
emulsion adjuvant, consisting of Squalene, Poloxamer 401 (Pluronic® L121) and 171 
Polysorbate 80 (33). Vaccine lots 387BYC01L and 387BYA08A were used in 2011 and 172 
2012, respectively. Each dose was administrated via a single intramuscular injection in 173 
the neck of the animals.  174 
During June-July 2011 an initial double primary vaccination (two doses 175 
administrated 3 weeks apart) of 85 horses was performed (Fig. 1), while 33 horses were 176 
used so as to form the control group (Table 1). During May-June 2012, 79 of the 177 
aforementioned vaccinated animals received an annual booster immunization dose of the 178 
vaccine. Six of the original 85 horses were excluded during the second year for various 179 
reasons, e.g. they were moved out of the study area, or were euthanized due to causes 180 
irrelevant to WNV-infection. In addition, in May-June 2012, another 55 horses which 181 
were seronegative to WNV received a double immunization with the vaccine (Fig. 1). 182 
During this period, 21 of the 2011’s control animals which were determined as 183 
seronegative were kept, and along with 12 additional seronegative horses, were used as 184 
naïve controls for the 2012 epidemic period (Table 1). The total number of control horses 185 
(n = 45) was intentionally limited to approximately 33% of the total number of horses 186 
used in the study for humane reasons. In each participating horse riding club the 187 
vaccinated and control animals were co-mingled and managed similarly.  188 
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 189 
Clinical examination and blood samplings  190 
Physical and special neurological examination were being performed on each of 191 
the participating horses, at least one week prior to the initiation of immunizations, and 192 
until the end of the respective epidemic period. Monitoring was being performed 193 
regularly (every 5-6 days) for signs compatible with WNV infection, (e.g. anxiety, 194 
muscle fasciculation, head tremor, lip twitching, teeth grinding, ataxia, paresis, head 195 
shaking, etc.), along with any other abnormal conditions. Besides the evaluation for the 196 
presence of clinical signs due to WNV infection, horses were also being evaluated for 197 
local and systemic adverse reactions due to the vaccination. Clinical evaluations were 198 
done independent of knowledge of immunization status.  199 
Blood was collected from all horses in 10 ml plain vacuum tubes at specific time 200 
points. For the animals participating from 2011, these time points were W (week) 0, W3, 201 
W7, W21, W34, W48, W52, W66, and W72 (Fig. 1). For the animals that participated in 202 
the study only during 2012, the respective time points for blood collection were W45(0), 203 
W48(3), W52(7), and W72(27) (Fig. 1). Numbers in parentheses indicate the exact week 204 
number in which samplings were being conducted from the horses that participated only 205 
in 2012, beginning from the week that these animals received the first dose of the vaccine 206 
(0).  Numbers outside parentheses indicate the corresponding week number from the 207 
beginning of the study (2011). For example, W45(0) indicates week 0 for the horses 208 
participating in 2012 (conduction of the first immunization). Concomitantly, this is also 209 
week 45, counting from the day in which the first vaccine dose was administrated during 210 
2011 (W0). 211 
Additionally, for the confirmation of diagnosis of WNV infection in horses with 212 
neurological signs, blood samples were drawn shortly after clinical signs were being 213 
noticed. Blood was allowed to clot and tubes were centrifuged (3,000 × g, 10 min, 4 °C). 214 
Sera were transferred to clear 2 ml microcentrifuge tubes and stored at -80 °C until they 215 
were assayed.  216 
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 217 
Serological and virological testing 218 
Sera obtained from all control horses after the end of both 2011 and 2012 219 
epidemic periods (W21 and W72(27) of the study, respectively) were tested for WNV-220 
specific antibodies (indication of seroconversion), using a commercially available 221 
cELISA kit (ID Screen® West Nile Competition, ID.vet, Montpellier, France). This 222 
analysis was performed in order to confirm that the virus was circulating in the 223 
participating horse riding clubs, as well as to estimate the percentage of animals which 224 
were exposed to the virus during each epidemic period. 225 
In order to confirm that the vaccine induced the development of cross-protective 226 
immunity, sera obtained one month after the completion of the double primary 227 
vaccination course from all vaccinated horses of both years (W7 and W52(7), 228 
respectively) were tested for the presence of NAbs specifically directed against the Nea 229 
Santa-Greece-2010 lineage 2 strain, following an existing SNT protocol (39) with slight 230 
modifications. Briefly, after heat inactivation at 56 °C for 30 min, sera were two-fold 231 
serially diluted (1:5 to 1:2560, in duplicates in 96-well cell culture plates) in Dulbecco's 232 
Modified Eagle's Medium (DMEM; Invitrogen-Gibco, Groningen, The Netherlands), and 233 
50 μl of DMEM containing 100 TCID50 (50% tissue culture infectious doses) of the Nea 234 
Santa-Greece-2010 strain were added. Controls, reference sera and back titration of the 235 
antigen were also included. After incubation of the plates at 37 °C for 1.5 h, 2 × 104 Vero 236 
cells in 100 μl of DMEM with 2% penicillin (100 IU/ml) and streptomycin (100 μg/ml), 237 
2% sodium pyruvate and 10% fetal bovine serum (Invitrogen-Gibco, Groningen, The 238 
Netherlands) were added to every well. Plates were incubated at 37 °C for 5 days and 239 
wells were examined under an inverted light microscope for evidence of viral cytopathic 240 
effects. The NAb titer of each serum was calculated as the highest serum dilution in 241 
which protection of the cell monolayer was observed. Sera were being considered 242 
positive if cells were protected at a dilution ≥1:10. 243 
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Moreover, sera obtained from all primo-vaccinated horses (naïve horses which 244 
received the initial two-dose vaccination course) after the end of each epidemic period 245 
(November, W21 and W72(27) of the study) were also tested with the aforementioned 246 
SNT protocol and NAb titers were compared to the respective ones developed 1 month 247 
after the double primary vaccination (W7 and W52(7), respectively), so as to detect the 248 
occurrence of anamnestic humoral immune responses, indicative of natural infections.  249 
In order to evaluate the levels and the duration of the produced NAbs, 23 primo-250 
vaccinated animals of the first year (2011) which were not exposed to the virus as 251 
indicated by the results of the aforementioned analysis (~40% of the total number of 252 
vaccinated animals which were determined not to be exposed to WNV during that year), 253 
were tested at samples obtained from the day of the first immunization (W0), until one 254 
month after the annual booster (W52). SNTs were used to determine the NAb titers 255 
against two WNV strains; the Nea Santa-Greece-2010 lineage 2 strain, as well as the 256 
PaAn001/France lineage 1 strain (kindly provided by Dr. Sylvie Lecollinet, UMR 1161 257 
Virology, INRA-ANSES-ENVA, France).  258 
For the confirmation of the diagnosis in control horses with clinical signs, the 259 
collected serum samples were tested for the presence of WNV-specific IgM antibodies, 260 
using a commercially available IgM antibody capture enzyme-linked immunosorbent 261 
assay (MAC-ELISA; IgM WNV Ab Test, IDEXX-Istitut Pourquier, Montpellier, 262 
France), following the manufacturer’s instructions. Furthermore, RNA was extracted 263 
from the sera obtained of the horses with neurological signs using the NucleoSpin® RNA 264 
virus kit (Macherey-Nagel, Düren, Germany. Extracts were examined using a WNV-265 
specific, one tube real-time RT-PCR, using the primer pair WNPolUp (5’-266 
TTTTGGGAGATGGTGGATGARGA-3’) and WNPolDo2 (5’-267 
CCACATGAACCAWATGGCTCTGC-3’), at final concentration of 0.6 μM each, and 268 
the TaqMan probe WNPolProb2 (5’-FAM-TCTCTCTCTTTCCCATCATGTTGT-269 
ZNA5-BHQ1-3’ at a final concentration of 0.2 μM) targeting a 144 bp part of the 270 
nonstructural protein 5 (NS5) genomic region of WNV. The limit of detection was 271 
previously determined to be 1 TCID50/ml (40). Amplification reactions were run in a 272 
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total volume of 25 μl using 5μl of RNA extract and 20μl of reaction buffer of a 273 
commercial RT-PCR kit (One step RT-PCR Qiagen, Hilden, Germany). The thermal 274 
cycling conditions were as follows; 50 °C for 30 min, followed by 95 °C for 15 min and 275 
50 cycles in 2 steps: a) 95 °C for 30 sec (denaturation), and b) 60 °C for 40 sec 276 
(annealing and extension). The fluorescence levels were measured at the end of each 277 
cycle. The assay was performed using the CFX96 Touch™ Real-Time PCR detection 278 
system (Bio-Rad Laboratories, Hercules, CA, USA). Analysis of data was conducted 279 
using the CFX™ Software (Version 3.0, Bio-Rad Laboratories, Hercules, CA, USA).  280 
 281 
Statistical analysis 282 
The effect of immunization on the presence of clinical signs was assessed with an 283 
odds ratio and a mixed model analysis. 284 
The odds ratio analysis considered non-vaccinated animals as the control and 285 
vaccinated animals as the intervention (case) group. The odds ratio was calculated as 286 
follows (41): 287 
d
c
b
aOR =   [1] 288 
where OR = odds ratio, a = number of vaccinated horses with clinical signs, b = number 289 
of vaccinated horses without clinical signs, c = number of non-vaccinated horses with 290 
clinical signs and d = number of non-vaccinated horses without clinical signs. 291 
The significance of the odd ratio was assessed by the confidence interval which was 292 
calculated as follows: 293 
)}{ln(96.1)(ln(%95 ORSEOReCI ⋅±=   [2] 294 
where 95%CI = 95% confidence interval, ln = natural logarithm, SE = standard error and 295 
OR = odds ratio as in equation 1; the standard error was calculated as follows: 296 
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dcba
ORSE 1111)}{ln( +++=   [3] 297 
where SE = as in equation 2 and a, b, c, d = as in equation 1. 298 
 In order to accommodate possible values equal to zero in the calculation of the 299 
odds ratio or its standard error, 0.5 may be added to all cells (42-43). An odds ratio 300 
significantly smaller than unity would suggest that intervention (i.e., immunization), is 301 
better than the control. 302 
The mixed model analysis was based on the following model: 303 
ijklmlkjiijklm eAVSRCCYY +++++= µ   [4] 304 
where Y = presence or absence of clinical signs for the lth animal, μ = overall mean, CY = 305 
fixed effect of calendar year i (i = 2011-2012), RC = fixed effect of riding club j (j = 1-6), 306 
VS = vaccination status k (k = 0 for non-vaccinated and 1 for vaccinated animals), A = 307 
random animal effect reflecting the individual response of each horse and e = random 308 
residual. 309 
Model 4 fitted a logit function to account for the binary nature of the trait 310 
(presence or absence of clinical signs). The outcomes of this model served as 311 
confirmation of the odds ratio analysis with the additional benefit of the quantification of 312 
the vaccination effect on presence of clinical signs, adjusted for all other factors included 313 
in model 4. The mixed model analysis was conducted with the ASReml software (44). 314 
The two analyses, odds ratio and mixed model, were run once considering all 315 
animals and then a second time including only the infected horses. 316 
 NAb titers were used to calculate the geometrical mean titer (GMT) for each 317 
sampling time point and against each viral strain. The comparison of the GMTs against 318 
the two viral lineage antigens was performed at all sampling time points, using a paired 319 
two-tailed Student’s t-test. A value of P < 0.05 was considered to be statistically 320 
significant. In order to estimate the strength of the anamnestic immune responses (e.g. 321 
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due to the booster) between two sampling points (w, z) and against the same lineage (x), 322 
geometrical mean titer ratio (GMTR) was calculated as follows: GMTRx = GMTz / 323 
GMTw. 324 
 325 
Investigation of the immunological similarity between the vaccine and the circulating 326 
viral strains  327 
In an effort to interpret the immunological cross-reactivity between the NAbs 328 
produced against the vaccine strain (New York 1999/VM-2, GenBank Acc. No. 329 
AF260967) and the lineage 2 strain circulating in the study area (Nea Santa-Greece-2010, 330 
GenBank Acc. No. HQ537483), we compared the identity of the Envelope (E) protein 331 
peptide sequences of the two strains. Furthermore, the respective peptide sequence of a 332 
lineage 2 strain isolated in South Africa (SA93/01, Gen.Bank. Acc. No. EF429198) was 333 
included in these comparisons. Multiple alignments of E protein sequences were 334 
conducted using the MEGA v.6.06 software (45), and amino acid substitutions were 335 
visualized using BioEdit v.7.2.5 software (46). 336 
 337 
Animal ethics 338 
Animal studies have been performed in accordance to the International Guiding 339 
Principles for Biomedical Research involving animals, as issued by the Council for 340 
International Organizations of Medical Sciences. All horse owners gave their consent for 341 
the immunizations, blood sampling and serological testing prior to the commencement of 342 
the study. This study was performed in compliance with national guidelines and EU 343 
regulations, as well as by local Ethics Committees of the School of Veterinary Medicine, 344 
Aristotle University of Thessaloniki. 345 
 346 
Results 347 
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WNV circulation in the study area  348 
The presence and circulation of the virus in the study area was confirmed for both 349 
2011 and 2012, by studies conducted in captive sentinel chickens and mosquitoes, as 350 
already described (40, 47-48). Specifically, chickens were placed in cages in close 351 
proximity to the participating horse riding clubs, and exposed to mosquitoes throughout 352 
both epidemic periods, followed by serological and virological testing. Mosquitoes which 353 
were being collected throughout May-October of both years were also tested. Molecular 354 
characterization of the circulating viral strain during both 2011 and 2012 in chickens and 355 
mosquitoes confirmed that the virulent Nea Santa-Greece-2010 was the only strain 356 
detected in Central Macedonia (40, 47-48).  357 
 358 
WNV natural infections in control and immunized horses 359 
Serological testing of control horses during November of each year [W21, 360 
W72(27)] indicated that WNV circulated in all the participating horse riding clubs, 361 
during both 2011 and 2012 epidemic seasons. Specifically, 12 out of 33 control animals 362 
of 2011 (36%) and 9 out of 33 control animals of the 2012 period (27%) seroconverted to 363 
WNV as evidenced by cELISA testing (Table 1).  364 
Comparative evaluation of NAb titers of sera obtained from all primo-vaccinated 365 
animals one month after the double vaccination and after the end of each epidemic period 366 
(November), indicated that anamnestic humoral responses (WNV infections) were 367 
evident in 32 of 85 primo-vaccinated horses of 2011 (38% of the immunized horses) and 368 
in 14 of 55 primo-vaccinated horses of 2012 (26% of the horses which received a primary 369 
immunization during the later year). Specifically, GMT increased from 1:67 to 1:1083 370 
(GMTR = 16.2, ~log24-fold increase). Natural infections, during 2012, of those horses 371 
that were exposed for a second consecutive year could not be determined directly by 372 
SNTs (due to the booster), but were calculated indirectly based on the respective 373 
percentages of the seroconverted control horses, as well as on the percentages of primo-374 
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vaccinated horses in which anamnestic humoral responses due to infections were 375 
detected, for the two years. As a result, it is estimated that from the 52 horses which 376 
remained uninfected during 2011 and received an annual booster in 2012, 15 animals 377 
were subsequently infected from WNV during the second epidemic season (Table 1). 378 
Combinatory analysis of all these results obtained from serological testing applied 379 
in control and vaccinated horses indicate in total 44 out of 118 horses (37%) were 380 
infected during 2011. The respective infection rate for 2012 was estimated to be 27% 381 
(Table 1). Infection rates between the horse riding clubs ranged between 18 and 60% for 382 
2011 and between 18 and 47% for 2012. 383 
 384 
Vaccine safety 385 
Regarding the adverse reactions of the applied vaccine, only one out of 140 386 
immunized animals (0.7%) developed a local reaction, on the site of the injection. This 387 
was a mild swelling which was developed after the second injection of the first year, and 388 
it was observed again in the same animal after the annual booster. During the 389 
aforementioned occurrences, resolution of the lesion was observed within a few days, 390 
without any interventions, and without other effects on the health of the animal. 391 
 392 
Neutralizing antibody responses in immunized horses 393 
One month after the initial double vaccination, NAbs against the Greek lineage 2 394 
strain were induced in all vaccinated animals with a GMT of 1:102 (titer range: 1:40 to 395 
1:320). Briefly, in 67 out of the 140 vaccinated animals (47.9%; 95% CI: 39-56%), an 396 
intermediate neutralizing activity was observed (titers 1:40-1:80). Twenty-six of these 397 
animals developed a NAb titer of 1:40 and 41 animals were presented with a titer of 1:80. 398 
Higher neutralizing responses were observed in sera from the remaining 73 vaccinated 399 
animals (52.1%; 95% CI: 44-61%).  Nineteen out of the 46 primo-vaccinated horses of 400 
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2011 and 2012 (41%) which were subsequently infected (32 and 14, respectively) as 401 
determined by SNT (Table 1), had a NAb titer of 1:40 against the Nea Santa-Greece-402 
2010 strain, one month after the primary immunization course.  403 
Moreover, application of SNT in 23 of the 53 primo-vaccinated horses of 2011 404 
which were revealed to not be naturally infected indicated that GMTs against the lineage 405 
1 strain were higher than the respective titer against the lineage 2 strain, at all sampling 406 
points. NAbs in the sera of these animals were being consistently detected against the two 407 
viral lineage antigens, at all sampling points, and until the annual booster immunization 408 
(Fig. 2). However, paired t-test analysis revealed no significant differences in the GMTs 409 
against the two WNV strains in the sera of the 23 vaccinated horses, at all sampling 410 
points (P >0.28). Specifically, analysis of the NAb titers raised against the two viral 411 
lineage antigens one month after the completion of the double primary vaccination course 412 
(i.e. on W7) indicated that the GMT for lineage 1 was 1:175 (titer range: 1:80 to 1:320), 413 
while the respective value for lineage 2 was 1:112 (titer range: 1:40 to 1:160). Individual 414 
NAb titers indicated that in 9 out of 23 animals (39.1; 95% CI: 20-61%) NAb titers were 415 
the same against both antigens. In 13 out of 23 animals (56.5; 95% CI: 35-76%) titers 416 
against the lineage 1 antigen were higher than the respective titer raised against lineage 2 417 
by one serial dilution, while in one serum (4.4; 95% CI: 0.1-24%) a titer difference of 2 418 
dilutions between the two viral lineage antigens was observed. Further comparison of 419 
NAb titers throughout the year indicate that those for lineage 1 were consistently higher 420 
than the respective values determined for lineage 2. 421 
One month after the annual booster a strong titer increase was observed against 422 
both strains (Fig. 2). Achieved NAb titers were well above their initial peak (one month 423 
after the initial double primary vaccination). Specifically, ≥log24-fold titer increase was 424 
observed in all cases, regarding the NAb titers against both PaAn001/France lineage 1 425 
(GMTRlin.1 = 30.2) and Nea Santa-Greece-2010 lineage 2 (GMTRlin.2 = 27.5) strains. A 426 
similar degree of immunoreactivity (titer increase ≥4 two-fold serial dilutions) was also 427 
observed in the vaccinated animals which were naturally infected. In all these anamnestic 428 
immune responses NAb titers were determined to be ≥1:320. The GMT for lineage 1 one 429 
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month after the annual booster (i.e. on W52) was determined to be 1:1894 (titer range: 430 
1:640 to ≥1:2560), whereas the respective value for the lineage 2 antigen was 1:722 (titer 431 
range: 1:320 to 1:1280). In terms of NAb titer differences between the two viral lineage 432 
antigens, it was indicated that in 15 out of 23 animals (65.2; 95% CI: 43-83%) NAb titers 433 
against the lineage 1 antigen were higher than the respective titer raised against lineage 2 434 
by one serial dilution. In 7 out of 23 animals (30.4; 95% CI: 14-53%) titers differed by 435 
two serial dilutions, and in one serum (4.4; 95% CI: 0.1-24%) a titer difference of 3 436 
dilutions was observed. 437 
 438 
Clinical signs, confirmation of the diagnosis and cross-protective efficacy of the vaccine 439 
None of the 140 vaccinated horses (0%) showed any clinical signs related to 440 
WNV infection during both epidemic periods. In contrast, 3 out of 45 control animals 441 
(7%) showed clinical signs due to WNV infection. The odds ratio, considering all 442 
animals, was 0.0432 (95% CI: 0.0022-0.8534). The fact that the CI did not cross 1 443 
implies a statistically significant (P < 0.05) difference between vaccinated and non-444 
vaccinated horses with regards to presence of clinical signs. The same analysis based on 445 
the infected animals only (61 immunized and 21 controls) returned an odds ratio of 446 
0.0423 (95% CI: 0.0021-0.08562), implying that immunization was also beneficial for 447 
animals that were naturally infected. 448 
More specifically, during the 2011 epidemic period, clinical signs were detected 449 
in one out of the 12 seroconverted control animals (August 13). During the 2012 450 
epidemic period, 2 out of the 9 seroconverted horses of the control group showed clinical 451 
signs (August 25 and September 8, respectively). These signs included fever, weakness 452 
of hind limbs, ataxia, muscle twitching and tremors in all 3 affected animals. Diagnosis 453 
was confirmed, as WNV-specific IgM antibodies were detected in all of them by MAC-454 
ELISA testing. WNV RNA was not detected (no Ct values obtained). Consequently, it 455 
was not possible to detect the virus in the obtained blood sera, since they were drawn 456 
after the initiation of the clinical signs and probably past the viremia stage. The 3 horses 457 
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received supportive treatment (dexamethasone, vitamin B complex supplements and 458 
phenylbutazone) that led to the resolution of clinical signs within a few days. 459 
The effect of vaccination on preventing clinical signs was confirmed and 460 
quantified with mixed model analysis. Vaccination status had a significant effect on 461 
clinical signs, with non-immunized animals being associated with a 7.58±1.82% (P < 462 
0.05) higher chance of exhibiting signs compared to immunized animals. This value was 463 
derived from the analysis of all animals with mixed model 4. The value reflects the effect 464 
of immunization on the presence of clinical signs and describes the difference between 465 
the marginal means of vaccinated and non-vaccinated animals, adjusted for all other 466 
effects in model 4. The corresponding value from the analysis of infected animals only 467 
was 14.22±1.43% (P < 0.05), suggesting that the vaccination effect was even stronger for 468 
naturally infected horses. 469 
 470 
E protein amino acid sequence comparisons 471 
For the interpretation of the reactivity between the NAbs raised against the 472 
vaccine strain and virus strains belonging to lineage 2, the immunological similarity of E 473 
protein peptide sequences was investigated. No differences were observed between the 474 
peptide sequences of the Greek and African lineage 2 strains. Sequence comparison of 475 
the lineage 1 vaccine strain with those of the lineage 2 strains, indicated 23 amino acid 476 
substitutions. Specifically, 3 of these substitutions were observed in structural domain I 477 
(DI; L131Q, V159I, and A172S), 15 substitutions were identified in DII (E55D, T64S, K71R, 478 
D83E, R93K, S122T, I126T, R128W, T129I, N199S, T205S, T208A, T210S, V232T, and I253V), 2 479 
substitutions were present in DIII (L312A, and A369S), and 3 more substitutions were 480 
found in the transmembrane domain/stem region (K413R, V442I, and L483M) (Fig. 3). 481 
 482 
Discussion 483 
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Two doses of the vaccine, administrated 3 weeks apart in immunologically naïve 484 
horses resulted in the development of adequate cross-protective immunity against 485 
development of neurological signs due to natural infections from the Nea Santa-Greece-486 
2010 lineage 2 strain during the following epidemic period, as indicated by the lack of 487 
occurrence of clinical signs in any of the immunized animals. Immunization using the 488 
aforementioned vaccine may not prevent horses from being infected from lineage 2 489 
strains, but can reduce the number of viremic horses, the viremia duration and titer in the 490 
infected animals, the duration and severity of clinical signs and the mortality, as it has 491 
already been described (34, 37). In our case, although detection of severe cases in horses 492 
was effective due to the experience of the involved veterinarians, it is possible that mild 493 
clinical occurrences could have not been not iced. However, since no supportive 494 
treatment was required, the impact of these cases was insignificant. Adverse reactions 495 
due to the vaccine were minimal. Our findings confirm that although the majority of 496 
infections in horses were subclinical, a high percentage (14%) of the seroconverted non 497 
vaccinated horses exhibited neurological signs. This is in agreement to a similar 498 
percentage (19%) of neurological manifestations-to-infections reported for this virus 499 
strain during the 2010 epidemic in Greece (49). Interestingly, slightly lower morbidity 500 
(10%) within infected horses has been reported for lineage 1 WNV strains (50-52).  501 
Despite the use of adjuvants, long-term immunity is not a feature of inactivated 502 
vaccines. Although the duration of immunity for lineage 1 strains has been determined 503 
(12 months after the primary vaccination course) (33), relevant information for lineage 2 504 
is lacking. Previous studies with Equip® WNV have indicated that immunized horses 505 
maintained NAb titers ≥1:100 against lineage 1, for 5-7 months, as determined by plaque 506 
reduction neutralization test (PRNT) (53). In another study it was shown that neutralizing 507 
responses were maintained for 6 months after vaccination of immunologically naïve 508 
horses (54). In a more recent study, it has been demonstrated that NAbs could be detected 509 
at samples obtained one year after the primary vaccination course of naïve horses, 510 
although a decline in neutralizing titers was observed (55). In our case, NAbs against the 511 
lineage 2 strain were developed in all vaccinated animals (titer range: 1:40 to 1:320, 512 
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GMT = 1:102) one month after the initial double vaccination. Although a titer decline 513 
was observed through time, as evidenced by testing of vaccinated animals that were not 514 
infected (GMT < 1:100 on week 34), NAbs were detectable until the annual booster. The 515 
lowest neutralizing response of 1:40 against the lineage 2 strain was observed in 41% of 516 
the primo-vaccinated horses of both years (n = 19) which were subsequently infected. 517 
The fact that these 19 horses did not exhibit clinical signs due to WNV infection indicates 518 
that NAb titers as low as 1:40 one month after the primary immunization course can be 519 
protective against natural infections from the Nea Santa-Greece-2010. It can be 520 
hypothesized that humoral immunity against lineage 2 lasts at least until W21, based 521 
solely on the GMTs against the lineage 2 strain which were >1:100 for these sampling 522 
time points, although individual titers >1:100 were detected until W34. GMTs against the 523 
PaAn001/France lineage 1 were higher than the respective titers against lineage 2, which 524 
is in agreement with other studies (36, 55). In our case comparison of GMTs against the 525 
two lineages revealed no significant differences. The applied immunization scheme 526 
resulted in development of adequate B-cell memory, as indicated by the strong responses 527 
observed after annual boosters and natural infections. Results regarding these responses 528 
are supported by a previous study, in which significant NAb titer increase (log25-fold) 529 
against both lineages is described, and titers achieved were well above their peak 530 
observed after the initial vaccination (55). It has been previously demonstrated that 531 
horses immunized with this vaccine also developed antigen-specific cellular responses 532 
(CD4+ and CD8+ IFN-γ expression, cellular proliferation and IL-4 expression in CD4+ 533 
PBMCs) (54), indicating that, besides humoral immunity, the vaccine induces T-cell 534 
responses, which might have an additional contribution to the cross-protection of the 535 
naturally infected horses.   536 
WNV E protein is a major determinant of tropism and the primary target of NAbs. 537 
Neutralizing epitopes have been identified mainly on DIII of E protein, and specifically, 538 
on residues 306, 307, 330 and 332 (56-58). Additional neutralizing epitopes have been 539 
identified on several residues of DI and DII, although the observed neutralizing activity 540 
for these regions is weaker (59). In our case, no changes were observed at residues S306, 541 
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K307, T330 and T332, which serve as major DIII neutralizing epitopes (56-58). However 542 
escape from neutralization has been associated with the L312A substitution, which was 543 
present in “Nea Santa-Greece-2010”, as it is in several WNV strains (60). No changes 544 
were observed in residues W101, G106 and L107, antigenic sites of the fusion loop located 545 
within DII (DII-FL, residues 98-109), which act as target of cross-NAbs among different 546 
species of the genus Flavivirus (61-63). Despite the L312A substitution, the findings of 547 
the present study ultimately suggest that under field conditions, adequate cross-548 
neutralization is capable of providing a high degree of protection.  549 
Different WNV lineages, characterized by varying virulence and 550 
neuroinvasiveness co-circulate in Europe (63), and knowledge regarding the cross-551 
protection is prerequisite. However, since outbreaks in horses were limited and 552 
unpredictable, immunizations have been performed extensively (26), regardless the 553 
degree of cross-protection between circulating and the vaccine strain. For the purpose of 554 
in-field evaluations of arbovirus vaccines, identification of the circulating strain 555 
comprises a necessity. In our case, it was not possible to detect the virus in the affected 556 
horses. This was anticipated, given that in horses WNV detection is hampered by the 557 
short viremia duration which precedes the onset of clinical signs (7, 49, 51). Therefore, 558 
WNV surveillance data from birds and mosquitoes, indicating that the only strain 559 
circulating during both years was the Nea Santa-Greece-2010 were utilized (46-48). 560 
Mixed model analysis seems to be a more accurate approach for in-field vaccine 561 
evaluations, as many factors are involved and should be taken into consideration. It was 562 
also possible to quantify the favorable effect of the immunization on the presence of 563 
clinical signs. Immunizations using inactivated lineage 1 vaccines can effectively protect 564 
horses from the development of neurological signs due to natural infections of virulent 565 
lineage 2 WNV strains. Since pathogenesis and antiviral immune responses against WNV 566 
in horses and humans are similar, our results could be of value in the future, for the 567 
possible evaluation of a candidate human vaccine. 568 
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Figure captions 795 
Fig. 1. Timeline of the immunizations and blood serum samplings performed in horses, 796 
for the evaluation of the cross-protective immunity offered from the inactivated vaccine. 797 
Black syringes indicate the double primary vaccinations; white syringe indicates annual 798 
booster vaccination. Arrows depict the time points of blood serum samplings. Weeks in 799 
which these samplings were conducted are displayed above the arrows. The two black 800 
arrows marked with asterisks (∗) depict samplings performed one week prior to the 801 
initiation of the primary vaccinations of 2011 and 2012, respectively, in order to detect 802 
and select WNV-seronegative horses. 803 
Fig. 2. Neutralizing antibody (NAb) geometrical mean titers (GMTs) of 23 immunized 804 
horses which were not infected, against the Nea Santa-Greece-2010 lineage 2 strain (grey 805 
curve, ) as well as the PaAn001/France lineage 1 strain (black curve, ▲). SNTs were 806 
performed in sera collected from W0 (time of the first dose of the double primary 807 
vaccination in 2011) and until W52 (i.e., one month after the annual booster 808 
immunization). Paired t-test analysis revealed no significant differences in the NAb 809 
GMTs against the two antigens, at all sampling points (P >0.28). Range error bars 810 
encompass the range of the individual NAb titers against each antigen, and for every 811 
sampling time point. Geometrical mean titer ratio (GMTR) calculated for the annual 812 
booster against each strain is also presented.  813 
Fig. 3. Alignment of the E protein amino acid sequences from the vaccine lineage 1 strain 814 
“New York 1999/VM2” (GenBank Acc. No. AF260967), the circulating lineage 2 strain 815 
“Nea Santa-Greece-2010” (GenBank Acc. No. HQ537483), and the South African 816 
lineage 2 strain “SA93/01” (GenBank Acc. No. EF429198) of West Nile virus. Dots 817 
indicate amino acid identities. The domains are indicated by bars, as explained at the 818 
figure legend. Investigation of the immunological similarity between the three peptides 819 
revealed no differences between the two lineage 2 strains. Comparison of the lineage 1 820 
(vaccine) and the lineage 2 peptide sequences of the E protein revealed 23 amino acid 821 
substitutions.  822 
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Table 1. Numbers of immunized and control horses which were included in the efficacy 823 
study during 2011 and 2012. Numbers and infection rates of horses per year, as well as 824 
numbers of horses which exhibited neurological signs due to WNV infection are also 825 
included in the table.  826 
 2011 2012 
Horse group IH (WNV-
seronegative, 
primo-
vaccinated) 
CH (WNV-
seronegative) 
IH (WNV-
seronegative, 
primo-
vaccinated) 
IH (primo-vaccinated 
in 2011 but not 
infected, received 
annual booster vaccine 
dose in 2012) 
CH (WNV-seronegative 
of 2011 but not infected 
+ WNV-seronegative, 
selected in 2012) 
No. of horses per 
group 
85 33 55 52 33 (21+12) 
No. (%) of WNV 
naturally infected 
horses determined by 
cELISA and/or SNT 
32/85 (38%) 12/33 (36%) 14/55 (26%) ID: 15/52 (29%) 9/33 (27%) 
No. (%) of WNV 
naturally infected 
horses with cinical 
signs, confirmed by 
MAC-ELISA 
0/32 (0%) 1/12 (8%) 0/14 (0%) 0/15 (0%) 2/9 (22%) 
Total No. (%) of 
infected horses per 
year 
44/118 (37%) 38/140 (27%) 
IH, immunized horses; CH, control horses; cELISA, competitive enzyme-linked 827 
immunosorbent assay; SNT, serum neutralization test; ; MAC-ELISA, IgM antibody 828 
capture enzyme-linked immunosorbent assay; ID, indirect determination 829 
 830 
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